Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter “Real-World” Study

MLA

Herishanu, Yair, et al. “Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter ‘Real-World’ Study.” Blood, vol. 138, no. 1, Number 1 Supplement 1, Nov. 2021, p. 2641. EBSCOhost, https://doi.org/10.1182/blood-2021-146848.

APA

Herishanu, Y., Levi, S., Goldschmidt, N., Morabito, F., Bairey, O., Del Poeta, G., Ziv Baran, T., Fineman, R., Mauro, F. R., Gutwein, O., Reda, G., Ruchlemer, R., Sportoletti, P., Laurenti, L., Shvidel, L., Coscia, M., Tadmor, T., Varettoni, M., Aviv, A., … Gentile, M. (2021). Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter “Real-World” Study. Blood, 138(1, Number 1 Supplement 1), 2641. https://doi.org/10.1182/blood-2021-146848

Chicago

Herishanu, Yair, Shai Levi, Neta Goldschmidt, Fortunato Morabito, Osnat Bairey, Giovanni Del Poeta, Tomer Ziv Baran, et al. 2021. “Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter ‘Real-World’ Study.” Blood 138 (1, Number 1 Supplement 1): 2641. doi:10.1182/blood-2021-146848.